Ongoing clinical trials of PI3K/Akt/mTOR and MAPK pathway-targeted therapy in UC
| Drugs | Taegets | Combination | Conditions | Phase | NCT |
|---|---|---|---|---|---|
| Copanlisib | PI3Kα/δ | Avelumab | Adv UC | I/II | NCT05687721 |
| Ipatasertib | Akt | Null | Adv UC | II | NCT02465060 |
| Sapanisertib | mTOR1/2 | Null | Adv UC | II | NCT03047213 |
| Tipifarnib | RAS | Null | UC | II | NCT02535650 |
| Sorafenib | RAF | gemcitabine and cisplatin | UC | II | NCT01222676 |
| Vistusertib | mTOR | Null | UC | MIBC | I | NCT02546661 |
Null in combination indicates that the trial is monotherapy. MAPK: mitogen-activated protein kinase; UC: urothelial carcinoma; PI3K: phosphatidylinositol 3-kinas; Akt: protein kinase B; mTOR: mammalian target of rapamycin; MIBC: muscle-invasive bladder cancer; Adv: advanced; RAS: sat sarcoma; RAF: rapidly accelerated fibrosarcoma; NCT: National Clinical Trial; |: and